Capricor Therapeutics, Inc. (CAPR) Stock

Understand Capricor Therapeutics, Inc.: how it makes money

Capricor Therapeutics develops cell and exosome-based therapies, including its allogeneic cardiac-derived cell therapy CAP-1002, and it makes money only from small-scale commercialization revenue so far while the main value driver is advancing clinical trials.

Because Capricor is still primarily a clinical-stage therapy developer with essentially no revenue, its profit model depends on turning clinical progress (trial participation and outcomes) and manufacturing scale-up (doses per year capacity) into future commercialization, rather than existing product sales.

Business quality (Weak): A development-stage biotechnology company, current financial performance is heavily loss-making, and the most measurable operating progress comes from trial enrollment and building manufacturing capacity.

Bull case

• CAP-1002 phase progress: CAP-1002 has completed a phase III clinical trial for late-stage Duchenne muscular dystrophy (DMD), and it is in a phase II clinical trial for cytokine storm associated with SARS-CoV-2.
• Defined trial enrollment metrics: In HOPE-3, it reports 105 patients enrolled (Cohorts A and B) and 17 active sites, with planned sample size of 106.
• Manufacturing scale-up readiness: It reports commercial manufacturing capacity at full capacity of 10,000 doses per year, and it also reports doses per year from the San Diego facility of 1,000.
• Safety signal tracking: It reports 800 Deramiocel infusions demonstrating a consistent safety profile.

Bear case

• Revenue is minimal: For the quarter ended 2024-09-30, revenue is reported as 0.0B, and commercialization revenue is shown as 0.01B in the provided segment candidates.
• Large operating losses: The operating margin for the quarter ended 2024-09-30 is -575.2%, indicating the business is not yet converting operations into profits.
• Execution and timing risk remain: Key HOPE-3 planning and ramp metrics are still in motion (for example, number of subjects randomized in HOPE-III is 48 and active sites are 17, while planned enrollment is 106).

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Rocket Pharmaceuticals, Inc. (RCKT)
• Arcturus Therapeutics Holdings Inc. (ARCT)
• Lyell Immunopharma, Inc. (LYEL)
• Upstream Bio, Inc. (UPB)
• Perspective Therapeutics, Inc. (CATX)
• Galectin Therapeutics Inc. (GALT)
• DiaMedica Therapeutics Inc. (DMAC)
• Abeona Therapeutics Inc. (ABEO)